Following a full submission
AWMSG advice |
||
Status: Recommended with restrictions | ||
Buprenorphine/naloxone (Suboxone®) is recommended for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. In accordance with NICE guidance such treatment should be considered in patients who are unsuitable for maintenance treatment with methadone. |
||
|
||
Medicine details |
||
Medicine name | buprenorphine / naloxone (Suboxone®) | |
Formulation | 8 mg / 2 mg sublingual tablet and 2 mg / 0.5 mg sublingual tablet | |
Reference number | 70 | |
Indication | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction |
|
Company | Merck Sharp & Dohme Ltd | |
BNF chapter | Central nervous system | |
Submission type | Full | |
Status | Recommended with restrictions | |
Advice number | 1108 | |
NMG meeting date | 14/05/2008 | |
AWMSG meeting date | 13/06/2008 | |
Ratification by Welsh Government | 17/07/2008 | |
Date of issue | 18/07/2008 |